Evidence map›Paper›PMID 36233152›Full record

ArticleInternational journal of molecular sciences2022

Dynamic Epigenetic Changes during a Relapse and Recovery Cycle in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Amber M Helliwell, Peter A Stockwell, Christina D Edgar, Aniruddha Chatterjee, Warren P Tate

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Amber M HelliwellDepartment of Biochemistry, School of Biomedical Sciences, University of Otago, Dunedin 9016, New Zealand.
Peter A StockwellDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.ORCID 0000-0002-2145-3493
Christina D EdgarDepartment of Biochemistry, School of Biomedical Sciences, University of Otago, Dunedin 9016, New Zealand.
Aniruddha ChatterjeeDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.ORCID 0000-0001-7276-2248
Warren P TateDepartment of Biochemistry, School of Biomedical Sciences, University of Otago, Dunedin 9016, New Zealand.
University of Otago · NZ

Funding

Healthcare Otago Charitable Trust, Associated New Zealand Myalgic Encephalomyelitis Society (ANZMES), ME/CFS families NA
6 · The paper itself

Abstract

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex disease with variable severity. Patients experience frequent relapses where symptoms increase in severity, leaving them with a marked reduction in quality of life. Previous work has investigated molecular differences between ME/CFS patients and healthy controls, but not the dynamic changes specific to each individual patient. We applied precision medicine here to map genomic changes in two selected ME/CFS patients through a period that contained a relapse recovery cycle. DNA was isolated from two patients and a healthy age/gender matched control at regular intervals and captured the patient relapse in each case. Reduced representation DNA methylation sequencing profiles were obtained spanning the relapse recovery cycle. Both patients showed a significantly larger methylome variability (10-20-fold) through the period of sampling compared with the control. During the relapse, changes in the methylome profiles of the two patients were detected in regulatory-active regions of the genome that were associated, respectively, with 157 and 127 downstream genes, indicating disturbed metabolic, immune and inflammatory functions. Severe health relapses in the ME/CFS patients resulted in functionally important changes in their DNA methylomes that, while differing between the two patients, led to very similar compromised physiology. DNA methylation as a signature of disease variability in ongoing ME/CFS may have practical applications for strategies to decrease relapse frequency.

Indexed as

Fatigue Syndrome, ChronicEpigenesis, GeneticEpigenomicsHumansQuality of LifeRecurrenceDMAPDNA methylationEpigeneticsME/CFSRRBS

Identifiers

PMID36233152
PMCPMC9570248
OpenAlexW4303699577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.